Zionexa's F-18 radiopharmaceutical biomarker Cerianna (fluoroestradiol) was approved by the U.S. Food and Drug Administration last year for use in PET detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. The French company, formed in 2018, has several other biomarkers in its pipeline.
An estimated 168,000 people have metastatic breast cancer. Today, Cerianna is accessible to approximately 25% of the relevant patient population, according to a company release. GE Healthcare stated it aims to scale Cerianna to be accessible to a minimum of 75% of patients by 2023.
The financial terms of the acquisition were not disclosed.
Copyright © 2021 AuntMinnie.com